Javascript must be enabled to continue!
PWE-046 Early Clinical Experience of Endoclot™ in the Treatment of Acute Gastro-Intestinal Bleeding
View through CrossRef
Introduction
EndoClot
™
is a new novel haemostatic powder for the treatment of gastrointestinal bleeding. We report our initial experiences of EndoClot
™
as an adjunct haemostatic therapy. This is the first UK report of its endoscopic use in gastrointestinal bleeding.
Methods
EndoClot™ was used as an adjunct therapy in the treatment of continued bleeding following a therapeutic intervention, either for acute upper gastrointestinal bleeds, or after elective endoscopic mucosal resections. Up to 1g of AMP® (absorbable modified polymers) was applied in each patient using the EndoClot™ air compressor and applicator.
Results
EndoClot™ was used in a total of 6 patients, (5 men, 1 woman; aged between 49 and 83 years, mean age 68 years). In 2 patients, EndoClot™ was applied following endoscopic mucosal resection of a rectal polyp after bleeding was not resolved with cautery. In a further 2 patients, EndoClot™ was applied over a duodenal ulcer with endoscopic stigmata of recent haemorrhage when there was residual bleeding despite adrenaline injection and gold probe cautery. In another patient, EndoClot™ was applied following clipping of a spurting vessel at the gastro-oesophageal junction (likely Mallory-Weiss tear). In these 5 patients, application of EndoClot™ resolved any continued bleeding. There was also no rebleeding within 14 days of the procedure, no mortality or major adverse events.
A sixth patient had EndoClot™ applied to what was first thought to be a duodenal ulcer with a probable vessel, when there was residual bleeding despite adrenaline injection and gold probe cautery. This patient was re-scoped the following day after further bleeding and subsequent investigations confirmed a carcinoma of the pancreatic head with duodenal infiltration.
Conclusion
EndoClot™ appears to be a safe and effective adjunct to existing therapies in the treatment of gastrointestinal bleeding. Large prospective studies are required to establish its exact role alongside established methods of haemostasis.
Disclosure of Interest
None Declared.
Title: PWE-046 Early Clinical Experience of Endoclot™ in the Treatment of Acute Gastro-Intestinal Bleeding
Description:
Introduction
EndoClot
™
is a new novel haemostatic powder for the treatment of gastrointestinal bleeding.
We report our initial experiences of EndoClot
™
as an adjunct haemostatic therapy.
This is the first UK report of its endoscopic use in gastrointestinal bleeding.
Methods
EndoClot™ was used as an adjunct therapy in the treatment of continued bleeding following a therapeutic intervention, either for acute upper gastrointestinal bleeds, or after elective endoscopic mucosal resections.
Up to 1g of AMP® (absorbable modified polymers) was applied in each patient using the EndoClot™ air compressor and applicator.
Results
EndoClot™ was used in a total of 6 patients, (5 men, 1 woman; aged between 49 and 83 years, mean age 68 years).
In 2 patients, EndoClot™ was applied following endoscopic mucosal resection of a rectal polyp after bleeding was not resolved with cautery.
In a further 2 patients, EndoClot™ was applied over a duodenal ulcer with endoscopic stigmata of recent haemorrhage when there was residual bleeding despite adrenaline injection and gold probe cautery.
In another patient, EndoClot™ was applied following clipping of a spurting vessel at the gastro-oesophageal junction (likely Mallory-Weiss tear).
In these 5 patients, application of EndoClot™ resolved any continued bleeding.
There was also no rebleeding within 14 days of the procedure, no mortality or major adverse events.
A sixth patient had EndoClot™ applied to what was first thought to be a duodenal ulcer with a probable vessel, when there was residual bleeding despite adrenaline injection and gold probe cautery.
This patient was re-scoped the following day after further bleeding and subsequent investigations confirmed a carcinoma of the pancreatic head with duodenal infiltration.
Conclusion
EndoClot™ appears to be a safe and effective adjunct to existing therapies in the treatment of gastrointestinal bleeding.
Large prospective studies are required to establish its exact role alongside established methods of haemostasis.
Disclosure of Interest
None Declared.
Related Results
PTU-029 The Use Of Endoclot™ Therapy In The Endoscopic Management Of Gastrointestinal Bleeding
PTU-029 The Use Of Endoclot™ Therapy In The Endoscopic Management Of Gastrointestinal Bleeding
Introduction
Endoclot™ is a non-toxic topical haemostatic powder consisting of absorbable modified polymers. We previously described our ...
De Participatieve Waarde Evaluatie: ervaringen met een nieuwe vorm van grootschalige burgerparticipatie
De Participatieve Waarde Evaluatie: ervaringen met een nieuwe vorm van grootschalige burgerparticipatie
The Participatory Value Evaluation: experiences with a new form of large-scale citizen participation
The Participatory Value Evaluation (the Dutch abbreviation is PWE for...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
P677Association between bleeding after acute coronary syndrome and newly diagnosed cancers
P677Association between bleeding after acute coronary syndrome and newly diagnosed cancers
Abstract
Introduction
There is a growing body of evidence on the incidence and negative prognostic impact of post-discharge hemo...
P3843Ischemic-bleeding balance according to history of prior bleeding in patients with acute coronary syndrome during treatment with dual antiplatelet therapy
P3843Ischemic-bleeding balance according to history of prior bleeding in patients with acute coronary syndrome during treatment with dual antiplatelet therapy
Abstract
Introduction
ESC guidelines recommend short-term dual antiplatelet therapy (DAPT) in patients with high bleeding risk. ...
Antioxidant capacities, antidiabetic potentials, and mineral compositions of pap aqua and aqueous extracts from Ocimum gratissimum L.
Antioxidant capacities, antidiabetic potentials, and mineral compositions of pap aqua and aqueous extracts from Ocimum gratissimum L.
Introduction: This study appraised the antioxidant potentials, mineral compositions, and antidiabetic activities of pap water (aqua) extract (PWE) and aqueous extract (AE) from Oci...
GASTROINTESTINAL BLEEDING, DESCRIPTION, ETIOLOGY, EPIDEMIOLOGY, CLASSIFICATION, CLINICAL PRESENTATION, TREATMENT AND PROGNOSIS
GASTROINTESTINAL BLEEDING, DESCRIPTION, ETIOLOGY, EPIDEMIOLOGY, CLASSIFICATION, CLINICAL PRESENTATION, TREATMENT AND PROGNOSIS
Introduction: Gastrointestinal bleeding can be divided into 2 broad categories: upper and lower bleeding. The anatomical landmark that divides upper and lower bleeds is the ligamen...
Bleeding Risk Factors in Thrombocytopenic Patients with Hematologic Malignancies
Bleeding Risk Factors in Thrombocytopenic Patients with Hematologic Malignancies
Introduction
Despite prophylactic platelet transfusions, World Health Organization (WHO) grade ≥ 2 bleeding occurs in 50 to 70% of patients with hematologic malignan...

